US FDA Review Teams Face ‘Herculean’ Shift to Two-Month Timelines With New Voucher

 
• By Sue Sutter
  
CBER's Katherine Szarama (left) chats with ASGCT Chief Advocacy Officer Margarita Valdez Martinez. (Sue Sutter)

More from Cell & Gene Therapies

More from Advanced Technologies